SPX4,227.32-56.42 -1.32%
DIA337.32-2.60 -0.77%
IXIC12,682.95-282.39 -2.18%

BRIEF-Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS

BRIEF-Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS

Reuters · 07/28/2022 08:36
BRIEF-Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For Review Of NDA Resubmission For Treatment Of UCDS

- Acer Therapeutics Inc ACER:

  • ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA ACCEPTANCE FOR REVIEW OF NDA RESUBMISSION FOR ACER-001 FOR TREATMENT OF UCDS

  • ACER THERAPEUTICS INC - FDA DESIGNATED NDA AS A CLASS 2 RESUBMISSION AND SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF JANUARY 15, 2023.

Source text for Eikon: ID:

Further company coverage: ACER


(Reporting by Kannaki Deka)

((Kannaki.Deka@thomsonreuters.com;))